NASDAQ: NVCN TSX: NVC VANCOUVER, Jan. 26, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that it has commenced an underwritten public offering in the United States of 8,000,000 common shares of the Company, consisting of 6,340,000 common shares to be...
Read MoreNASDAQ: NVCNTSX: NVC VANCOUVER, Jan. 13, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced it will visit the Nasdaq MarketSite in Times Square in celebration of its Nasdaq listing. Neovasc is focused on revolutionizing how advanced heart disease is...
Read MoreNASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 1, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that the first patient has been enrolled in the European arm of its TIARA-I Early Feasibility Trial, a multinational, multicenter trial being conducted at centers...
Read More--Tiara receives conditional approval from FDA for Early Feasibility Study-- --Reducer Live Case completed successfully at TCT 2014-- NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 13, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced financial results for the three and nine months...
Read More